Preclinical data on a novel T-cell therapy based on engineered autologous regulatory T cells (GNTI-122, EngTregs) for the potential treatment of type 1 diabetes (T1D) were presented by Gentibio Inc.
Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has divulged new theophine GLP-1 receptor agonists reported to be useful for the treatment of diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, obesity, glucose intolerance, dyslipidemia, hyperinsulinemia and insulin resistance.
Eccogene (Shanghai) Co. Ltd. has presented new GLP-1 receptor agonists reported to be useful for the treatment of diabetes, obesity, atherosclerosis, hypertension, stroke, Parkinson’s disease, diabetic kidney disease and liver disease.
It is largely known that oral drug delivery for macromolecules is often limited by the degradative environment of the gastrointestinal tract. Researchers from the Massachusetts Institute of Technology and their collaborators have presented Robocap, an oral mucus-clearing drug-delivery capsule that enhances the gastrointestinal absorption of drugs.
Maze Therapeutics has presented glycogen [starch] synthase, muscle (GYS1) inhibitors reported to be useful for the treatment of cancer and Pompe disease.
Gilead Sciences Inc. has patented glucagon-like peptide 1 (GLP-1) receptor agonists reported to be useful for the treatment of type 2 diabetes, obesity, prediabetes, atherosclerosis, metabolic syndrome, stroke, nonalcoholic steatohepatitis and renal disorders, among other disorders.
Hereditary tyrosinemia type 1 (HT1) is an inborn error of metabolism caused by deficiency of the fumarylacetoacetate hydrolase (FAH) enzyme and people with it are unable to metabolize the amino acid tyrosine. Toxic metabolites accumulate in the liver leading to severe oxidative damage.
Eli Lilly & Co. has synthesized macrocyclic peptides acting as amylin receptor agonists, glucose- and/or triglyceride-lowering agents reported to be useful for the treatment of type 2 diabetes, obesity, dyslipidemia and nonalcoholic steatohepatitis.
RSS
